Ai Technology Group INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OTC.Pink
AI Technology Group Inc. has amended its merger agreement with AVM Biotechnology and Biomed 360, extending the closing date to December 31, 2026, to accommodate financial audit requirements.
OTC.Pink
AI Technology Group Inc. filed an amendment to its 8-K, updating details of its acquisition of AVM Biotechnology Inc., including an increase in convertible debentures.
OTC.Pink
AI Technology Group Inc. amended its merger agreement with AVM Biotechnology Inc. and Biomed 360 Solutions Corp., extending the closing date to July 26, 2026, and revising investment tranches.
OTC.Pink
AI Technology Group Inc. announced plans to change its name to AVM Biotechnology, Inc., pending FINRA review.
OTC.Pink
AI Technology Group Inc. has amended its merger agreement with AVM Biotechnology Inc. and Biomed 360 Solutions Corp., extending the closing date and revising investment tranches due to financial audit obligations.
OTC.Pink
AI Technology Group Inc. and AVM Biotechnology Inc. announced an extension of funding dates for their proposed merger and the re-commencement of AVM's FDA Phase 2 Clinical Trial for AVM0703.
OTC.Pink
AI Technology Group Inc. has completed the acquisition of AVM Biotechnology Inc., making AVM a wholly-owned subsidiary in a tax-free reorganization.